biliary atresia

News

Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.

News

ADC Therapeutics' chances of upgrading its accelerated approval for DLBCL therapy Zynlonta to a full approval have taken a knock.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.